

## Dapagliflozin as a Cardio-Renal-Metabolic Drug

### Welcome address



#### Prof. Dr. Sadanand R Shetty

MD, DM, FACC, FSCAI, FACA (USA), FCPS, FISE.  
Co. Founder CCA International, Founder CVD India.  
Director, Cardiology Division,  
Somaiya Superspeciality Hospital, Sion.  
Emeritus Professor, Dr. D. Y. Patil University,  
Mumbai.

### Moderator



#### Dr. V T Shah

MD, FCSI, FSCAI, FACC.  
Co. Founder CCA International.  
Sr. Interventional Cardiologist,  
Raheja Fortis Hospital, Saifee Hospital,  
Surana Sethia Hospital, Breach Candy Hospital,  
Mumbai.



### International Speaker



#### Herr. Prof. Dr. Michael Böhm

MD, FESC  
"Co-Investigator in DAPA-HF Trial"  
Director of Cardiology, Internal and  
General Medicine, University of Saarland,  
Homburg, Germany.

### Panelist



#### Dr. K Kannan

MD, DM(Card), FACC.  
Consultant Cardiologist,  
Aswene Soundra Hospital & Research Centre,  
Chennai.

### Panelist




#### Dr. Rahul Patil

MBBS, MD, DNB(CARD),  
MNAMS, FICN, FESC, FACC (USA),  
FSCAI (USA)  
Consultant Cardiologist,  
Ruby Hall Clinic,  
Pune.

With an academic support from



to join the session



## Dapagliflozin as a Cardio-Renal-Metabolic Drug

### Agenda

Time	Duration	Session	Speakers
7.00 - 7.05 pm	5 min	Welcome	Dr. Sadanand Shetty
7.05 - 7.15 pm	10 min	Guideline Directed Therapy for HFrEF	Dr. V T Shah
7.15 - 7.50 pm	35 min	Dapagliflozin as a Cardio-Renal-Metabolic Drug	Prof. (Dr). Michäel Bohm
7.50pm - 8. 25 pm	35 min	Discussion	Moderator: Dr. V T Shah Panelists: Dr. Michäel Bohm, Dr. Sadanand Shetty, Dr. K Kannan, Dr. Rahul Patil
8.25- 8.30 pm	5 min	Concluding Remarks	Dr. V T Shah
8.30 - 8.35 pm	5 min	Vote of Thanks	Dr Sadanand Shetty



to join the session

With an academic support from

